(Adnkronos) - “La flessibilità di guselkumab permette ai pazienti con mici di poter scegliere il trattamento in base alle loro esigenze. Questo è un fattore molto importante che ci avvicinerà sempre di più al poter trattare i pazienti sulla base dei loro bisogni nell’ambito di una medicina personalizzata” ha spiegato Olga Maria Nardone, ricercatore e gastroenterologa presso l’università Federico II di Napoli nel corso del Congresso dell’Italian Group of Inflammatory Bowel Disease. Durante l’appuntamento di Riccione, Johnson & Johnson ha presentato importanti novità per il trattamento delle malattie infiammatorie croniche intestinali.
Category
🗞
NewsTranscript
00:00What is the role of the GuseccoMab?
00:04The GuseccoMab represents a step forward,
00:08a step towards the personalization of the treatment.
00:12The flexibility, both in terms of dosage,
00:15but above all in terms of supply,
00:18with the availability both in subcutaneous and endovenous form,
00:23will allow our patients to choose the treatment
00:28based on their needs.
00:30And this is a very important factor
00:32that will bring us closer and closer
00:34to be able to treat patients
00:36on the basis of their needs
00:39in the field of personalized medicine.
00:42It is also important to underline
00:44how the treatment of GuseccoMab
00:47is a treatment that is able to achieve goals
00:51that are more and more complicated,
00:53more and more ambitious.
00:55Composite goals, such as endoscopy
00:58in association with histology,
01:00which is fundamental, especially in colitis ulcerosa,
01:03and how the maintenance of these goals
01:06is in the long term.
01:08So not only in the induction phase,
01:10but also in the long term,
01:12which is the most important thing,
01:14because we don't have to and we don't want to
01:16stop only at the short term,
01:18but we have to look forward,
01:20always there, because only in this way
01:22we can block and alter
01:24the progressive course of these pathologies.
01:27Therefore, the achievement of the goals
01:29and the data they have shown in the long term
01:31is certainly a fundamental value.
01:34But above all, there is also
01:36the remission of corticosteroids,
01:39which is another fundamental goal,
01:41because the steroids, as we have seen,
01:44lead to many side effects.
01:46So the fact of being able to get rid of steroids
01:49and thus guarantee the remission,
01:51not only from a clinical point of view,
01:53but also endoscopically and histologically,
01:55is certainly a step forward
01:57towards the so-called
01:59disease modification trials,
02:01which therefore allow
02:03to go further and further
02:05and to try, in this way,
02:07to block
02:09the course of these pathologies.
02:11And everything, of course,
02:13is accompanied by the safety data,
02:15because it is essential
02:17that the goals are guaranteed
02:19also in terms of safety.
02:21And we have seen that Guselkom
02:23and the whole class of antiretroviral drugs 23
02:25have a high level of safety,
02:27and therefore this is essential
02:29to ensure
02:31that patients
02:33adhere to the treatment
02:35and therefore can carry out the treatment
02:37without fear of what may be
02:39the potential side effects.